Core Viewpoint - The research identifies Desmocollin 2 (DSC2) as the primary entry receptor for Epstein-Barr virus (EBV) infection in epithelial cells, providing a significant foundation for future studies and potential therapeutic developments against EBV infections [2][3][5]. Group 1 - The study utilized CRISPR-Cas9 screening technology to confirm that DSC2 is the main receptor for EBV entry in epithelial cells [3][5]. - Knocking out the DSC2 gene reduced EBV infection in nasopharyngeal and gastric epithelial cell lines, while restoring DSC2 expression reinstated the infection [6]. - The research found that DSC2 directly binds to EBV glycoproteins H and L through its extracellular domain, particularly the preEC-EC2 region, which can be targeted by polyclonal antibodies to block EBV infection in primary epithelial cells [7]. Group 2 - The findings contribute to the development of animal models for EBV infection, which are currently unavailable, thus facilitating the research and development of therapies targeting EBV infections [9].